Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio (2020 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Interest Coverage Ratio came in at 2.82 in Q2 2026, up 1170.12% YoY from 0.22 in Q2 2025, and down 27.25% on a QoQ basis from 3.88 in Q1 2026.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 14 years of Interest Coverage Ratio data on file, last reported at 2.82 in Q2 2026.
- Quarterly Interest Coverage Ratio rose 1170.12% year-over-year to 2.82 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 5.11 (up 677.24% YoY) and the FY2025 annual result came in at 1.99, up 3230.44% from the prior year.
- Interest Coverage Ratio slipped to 2.82 in Q2 2026, from 3.88 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 1317.18 in Q4 2025 to a low of 7.65 in Q2 2023.
- A 5-year average of 72.07 and a median of 1.73 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio sank 132.32% — and 2025, when it jumped 48913.53%.
- Tracing ALNY's Interest Coverage Ratio over 5 years: stood at 6.31 in 2022, then soared by 41.09% to 3.71 in 2023, then grew by 27.35% to 2.7 in 2024, then jumped by 48913.53% to 1317.18 in 2025, then plunged by 99.79% to 2.82 in 2026.
- The last three Interest Coverage Ratio figures came in at 2.82 (Q2 2026), 3.88 (Q1 2026), and 1317.18 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 1,199.14 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.82 |
| Mar 31, 2026 | 3.88 |
| Dec 31, 2025 | 2.01 |
| Sep 30, 2025 | 8.29 |
| Jun 30, 2025 | -0.26 |
| Mar 31, 2025 | 0.31 |
| Dec 31, 2024 | -2.70 |
| Sep 30, 2024 | -2.24 |
| Jun 30, 2024 | 1.46 |
| Mar 31, 2024 | -1.23 |
| Dec 31, 2023 | -3.71 |
| Sep 30, 2023 | 6.92 |
| Jun 30, 2023 | -7.65 |
| Mar 31, 2023 | -5.17 |
| Dec 31, 2022 | -6.31 |
| Sep 30, 2022 | -6.28 |
| Jun 30, 2022 | -4.50 |
| Mar 31, 2022 | -3.46 |
| Dec 31, 2021 | -5.28 |
| Sep 30, 2021 | -4.51 |